Another busy month on the FDA calendar has gone by but not without its fair share of hurrahs and heartaches. This is not unexpected, given the uncertainties characterizing drug development and approval processes, which in turn manifest as volatility in stocks belonging to the biotech space.
from RTT - Biotech http://ift.tt/297fa54
via IFTTT
No comments:
Post a Comment